Short Interest in Cingulate Inc. (NASDAQ:CING) Decreases By 95.8%

Cingulate Inc. (NASDAQ:CING) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 8,300 shares, a decline of 95.8% from the July 15th total of 199,100 shares. Based on an average daily volume of 54,100 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are sold short.

Cingulate Stock Up 16.6 %

Shares of CING traded up $0.41 during mid-day trading on Monday, reaching $2.85. 439,683 shares of the stock traded hands, compared to its average volume of 39,546. The firm has a fifty day moving average price of $0.51 and a 200 day moving average price of $0.94. Cingulate has a 1 year low of $1.82 and a 1 year high of $187.20.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.